Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00339495 · ClinicalTrials.gov registry record

Prostate Lung Colorectal and Ovarian (PLCO) Cancer Screening Trial

A clinical trial of Cancer and Death, sponsored by National Cancer Institute (NCI).

Active
Registry status
154,900
Enrollment target
1
Study location

NCT00339495 is a study of Cancer and Death that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 154,900 participants, above the 3,239-participant average among 615 other Cancer trials with a reported enrollment target (4682% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00339495, a study of Cancer and Death, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
154,900 participants
Enrollment target
1
Study location

Study Summary

The Division of Cancer Preventionl (DCP, formerly DCPC), under extramural contracts to 10 U.S. clinical centers, is evaluating the effectiveness of screening for prostate, lung, colorectal and ovarian cancer (The PLCO Trial). In 1996 the NCI Executive Committee approved the expansion of the PLCO Trial to collect additional materials and to conduct additional studies. About, 74,000 men and 74,000 women, aged 55-74 years, have been randomized on a 50/50 basis into screening or usual care arms. Additional blood is collected from screened subjects and saliva for buccal cells from control subjects. Pathologic tissues are obtained for selected cases that develop cancer or selected related diseases (e.g. colon polyps, benign prostatic hyperplasia). Additional questionnaire-based risk and disease-related information is also collected, withconfirmation of disease status from medical records. Genetic, biochemical and questionnairebasedrisk information will be related to the development of cancer and other diseases in this population. Volunteers who provide samples for these studies will not routinely receive their individual results from the Additional Investigation. Subjects requesting such information, however, will be provided their test results. In 2009 the NCI Executive Committee approved the Extended Follow-up of subjects beyond the original 13-year follow-up period. Participants will be reconsented for the release of records to a single NCI-Designated Central Data Collection Center (CDCC), which will administer the annual mailings containing the annual study update questionnaire and a brief (1-2 page) risk factor questionnaire. Individuals who do not consent to release their identifiers to the CDCC will be followed up passively through linkage to state cancer registries and the National Death Index. This protocol Review Application is for (1) the collaboration of intramural scientists in the Division of Cancer Epidemiology and Genetics (DCEG) in the Additional Studies

Conditions Studied

Study Locations (1)

Maryland

  • Westat, Inc. - Rockville

Trial Details

FieldValue
Enrollment Target 154,900 participants
Start Date 1998-05-01
Est. Completion 2026-12-31

Sponsor

National Cancer Institute (NCI)

3,257 total trials

What the Registry Record Tells You About NCT00339495

The ClinicalTrials.gov registry entry for NCT00339495 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 154,900 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 3,239-participant average among 615 other Cancer trials with a reported enrollment target (4682% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT00339495 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00339495 about?

NCT00339495 is a clinical study titled "Prostate Lung Colorectal and Ovarian (PLCO) Cancer Screening Trial". The Division of Cancer Preventionl (DCP, formerly DCPC), under extramural contracts to 10 U.S. clinical centers, is evaluating the effectiveness of screening for prostate, lung, colorectal and ovarian cancer (The PLCO Trial). In 1996 the NCI Executive Committee approved the expansion of the PLCO Tri...

What is the current status of trial NCT00339495?

This trial is currently active not recruiting. The enrollment target is 154,900 participants. The study started on 1998-05-01. Estimated completion is 2026-12-31.

What conditions does trial NCT00339495 study?

This clinical trial studies the following conditions: Cancer, Death.

Who is sponsoring clinical trial NCT00339495?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00339495 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.